Imagine shelling out thousands of dollars just to stay alive or manage a chronic condition—it's a harsh reality for many Americans facing sky-high drug prices that could bankrupt families. But what if I told you that former President Trump once stepped into the fray, vowing to shake up the pharmaceutical world if prices didn't drop?
Back in July, Trump sent a pointed letter to the heads of 17 major drug companies, laying out his expectations for them to slash costs and make medications more affordable for everyday people. You can read more about it here: (https://www.foxbusiness.com/politics/trump-leveling-global-medicine-playing-field). The core gripe? In the U.S., folks often fork over way more for treatments of everyday health issues compared to patients in other countries who get the same meds at a fraction of the cost. It's like paying premium for the same product just because of where you live—frustrating, right?
To give you a clearer picture, FOX Business has compiled a list of the five priciest drugs based on their U.S. sales figures, focusing on what consumers might actually pay out of pocket. Keep in mind, this doesn't factor in manufacturer coupons, insurance rebates, or special assistance programs that some lucky patients qualify for. These are blockbuster drugs that rake in billions, but at what cost to your wallet? Let's dive in, starting with the heavy hitters.
First up: Merck's Keytruda, a game-changer for fighting various types of cancer. For those new to this, Keytruda is an immunotherapy drug that helps the body's immune system target and destroy cancer cells—think of it as enlisting your own defenses in the battle. Each dose runs about $11,795 and is typically given every three weeks, which adds up fast during long-term treatment. Globally, it generated a whopping $29.5 billion in sales for 2024, according to Merck. If you're invested in pharma stocks, keep an eye on MRK (Merck & Co. Inc.), which closed at 84.42, up 0.51 or 0.61%—not bad for a company riding this wave.
But here's where it gets controversial: These lifesaving treatments are essential, yet their prices spark debates about profit versus patient access. Should companies charge less in wealthier markets to balance things out?
Next, Novo Nordisk's Ozempic, primarily prescribed for type 2 diabetes. This injectable helps control blood sugar levels by mimicking a hormone that tells your body you're full and slows digestion—super helpful for managing the disease that affects millions. A single weekly pen for a 28-day supply costs around $997.58. However, Novo Nordisk emphasizes to FOX Business that most insured patients—nearly 90%—pay $25 or less thanks to coverage and discounts. Off-label, it's a go-to for weight loss, even though the FDA hasn't greenlit it for that purpose yet. That dual use has sales soaring past $17 billion in 2024. Stock-wise, NVO (Novo Nordisk A/S) is at 48.47, with a slight uptick of 0.22 or 0.45%.
And this is the part most people miss: While Ozempic's popularity for shedding pounds is booming, does that justify the hype and potential shortages for actual diabetes patients? It's a hot topic—weight loss miracles or overhyped trend?
Coming in third: Eli Lilly's Mounjaro, which tackles both diabetes and has gained fame for weight loss support. Similar to Ozempic, it works by regulating blood sugar and appetite through weekly injections, making it easier for beginners to stick to treatment without constant monitoring. Expect to pay about $1,080 monthly for a 28-day supply of four pens. It pulled in $11.5 billion in global sales for 2024. For investors, LLY (Eli Lilly & Co.) is trading at 926.27, boosted by 18.72 or 2.06%—clearly, the market loves this one.
Shifting gears to heart health: Bristol-Myers Squibb and Pfizer's Eliquis, a blood thinner that prevents clots to reduce stroke and heart attack risks. If you're unfamiliar, blood thinners like this are crucial for people with irregular heartbeats or after certain surgeries, acting like a safeguard against dangerous blockages. Monthly costs hover between $500 and $600. It notched $11.4 billion in 2024 sales. Notably, Eliquis is one of 10 drugs targeted for price negotiations under the Inflation Reduction Act through Medicare, alongside others like Farxiga, Xarelto, and Januvia— a move that's already stirring the pot in Washington. Check BMY (Bristol Myers Squibb Co.) at 46.47, up 0.84 or 1.85%.
Finally, Gilead Sciences' Biktarvy for HIV treatment. This combo pill combines three antivirals to suppress the virus, allowing people with HIV to live healthier lives and prevent transmission— a true modern marvel in virology. It sets you back $2,000 to $3,000 per month. Sales hit $10 billion in 2024, per company reports. Gilead remains a leader in HIV meds, and their stock reflects that stability.
Wrapping this up, these drugs highlight the wild extremes in healthcare costs—lifesavers that come with a steep price tag. But is it fair that Americans pay more than our global neighbors, or does the U.S. system incentivize innovation worth the premium? What do you think: Should government intervention like Trump's threats or the Inflation Reduction Act go further to cap prices, even if it might slow new drug development? Drop your thoughts in the comments—agree, disagree, or share your own story. Let's keep the conversation going!
